<DOC>
	<DOCNO>NCT00782600</DOCNO>
	<brief_summary>This study test idea control release formulation CE-224,535 may allow less frequent dosing exposure low level drug immediate release formulation .</brief_summary>
	<brief_title>Study Controlled Release Formulations CE-224,535 Against Immediate Release Formulation Normal Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . A BMI low limit 17.5 kg/m2 may round 18.0 kg/m2 ; BMI upper limit 30.5 kg/m2 may round 30.0 kg/m2 acceptable inclusion . An informed consent document sign date subject legally acceptable representative . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding screen . Any conHistory regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Pharmacokinetics Immediate Release Oral Suspension Controlled Release Formulation</keyword>
</DOC>